Evidence map›Paper›PMID 37081485›Full record

Observational studyCritical care (London, England)2023

Major adverse cardiovascular events are associated with necroptosis during severe COVID-19.

Rosana Wiscovitch-Russo, Elsa D Ibáñez-Prada, Cristian C Serrano-Mayorga, Benjamin L Sievers, Maeve A Engelbride, Surya Padmanabhan, Gene S Tan, Sanjay Vashee, Ingrid G Bustos, Carlos Pachecho and 5 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury.Journal of cardiovascular development and disease · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Rosana Wiscovitch-Russo *Infectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Elsa D Ibáñez-Prada *Unisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia.
Cristian C Serrano-MayorgaUnisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia.
Benjamin L SieversInfectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Maeve A EngelbrideInfectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Surya PadmanabhanInfectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Gene S TanInfectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Sanjay VasheeInfectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Ingrid G BustosUnisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia.
Carlos PachechoUnisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia.
Lina MendezClinica Universidad de La Sabana, Chía, Colombia.
Peter H DubeDepartment of Microbiology, Immunology and Molecular Genetics, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
Harinder SinghInfectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA.
Luis Felipe Reyes *Unisabana Center for Translational Science, Universidad de La Sabana, Chía, Colombia. luis.reyes5@unisabana.edu.co.
Norberto Gonzalez-Juarbe *Infectious Diseases and Genomic Medicine Group, J Craig Venter Institute, 9605 Medical Center Drive Suite 150, Rockville, MD, 20850, USA. ngonzale@jcvi.org.
J. Craig Venter Institute · USUniversidad de La Sabana · COBoehringer Ingelheim (United States) · USUniversity of California San Diego · US

Funding

Elucidation of genetic networks of HSV-1 virion proteins and discovery of their functions in the morphogenesis of the infectious virus particleR01AI137365 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DESAI, PRASHANT J, VASHEE, SANJAY · 2019 to 2024
$3.2M
Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and diseaseR21AI148722 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI GONZALEZ-JUARBE, NORBERTO · 2020 to 2021
$542k
NIAID NIH HHS R01 AI137365NIAID NIH HHS R21 AI148722NIH HHS AI148722-01A1,NIH HHS R01AI137365
6 · The paper itself

Abstract

backgroundThe mechanisms used by SARS-CoV-2 to induce major adverse cardiac events (MACE) are unknown. Thus, we aimed to determine if SARS-CoV-2 can induce necrotic cell death to promote MACE in patients with severe COVID-19.

methodsThis observational prospective cohort study includes experiments with hamsters and human samples from patients with severe COVID-19. Cytokines and serum biomarkers were analysed in human serum. Cardiac transcriptome analyses were performed in hamsters' hearts.

resultsFrom a cohort of 70 patients, MACE was documented in 26% (18/70). Those who developed MACE had higher Log copies/mL of SARS-CoV-2, troponin-I, and pro-BNP in serum. Also, the elevation of IP-10 and a major decrease in levels of IL-17ɑ, IL-6, and IL-1rɑ were observed. No differences were found in the ability of serum antibodies to neutralise viral spike proteins in pseudoviruses from variants of concern. In hamster models, we found a stark increase in viral titters in the hearts 4 days post-infection. The cardiac transcriptome evaluation resulted in the differential expression of ~ 9% of the total transcripts. Analysis of transcriptional changes in the effectors of necroptosis (mixed lineage kinase domain-like, MLKL) and pyroptosis (gasdermin D) showed necroptosis, but not pyroptosis, to be elevated. An active form of MLKL (phosphorylated MLKL, pMLKL) was elevated in hamster hearts and, most importantly, in the serum of MACE patients.

conclusionSARS-CoV-2 identification in the systemic circulation is associated with MACE and necroptosis activity. The increased pMLKL and Troponin-I indicated the occurrence of necroptosis in the heart and suggested necroptosis effectors could serve as biomarkers and/or therapeutic targets. Trial registration Not applicable.

Indexed as

Cardiovascular DiseasesCOVID-19BiomarkersHumansNecroptosisProspective StudiesProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesSARS-CoV-2Troponin IBiomarkersProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesTroponin ICOVID-19Heart injuryNecroptosis

Identifiers

PMID37081485
PMCPMC10116454
OpenAlexW4366548326

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.